- $40.52m
- $22.11m
- $0.05m
Brief: Inmune Bio Reports Key Findings From Phase 2 Mindful Trial Of Xpro™ In Early Alzheimer’S Disease
INmune Bio's Alzheimer's drug falls short of mid-stage study goal, shares tumble (updated)
Brief: INmune Bio Reports Key Findings From Phase 2 MINDFuL Trial Of Xpro In Early Alzheimer’s Disease
INmune Bio's Alzheimer's drug fails to meet main goal in mid-stage study
Brief: Inmune Bio Announces About $19 Mln Registered Direct Offering
Brief: Xpro™ Reduces Amyloid And Enhances Behavior Post
INmune Bio Inc reports results for the quarter ended March 31 - Earnings Summary
INmune Bio Inc expected to post a loss of 47 cents a share - Earnings Preview
Brief: Inmune Bio Partners With Cell And Gene Therapy Catapult To Scale Up Cordstrom Manufacturing For Commercial Readiness
INmune Bio Inc reports results for the quarter ended December 31 - Earnings Summary
INmune Bio Inc expected to post a loss of 54 cents a share - Earnings Preview
Brief: OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower
Brief: Inmune Bio Inc. Announces Final Enrollment Of 208 Patients In Phase 2 Trial In Early Alzheimer's Disease
INmune Bio Inc reports results for the quarter ended in September 30 - Earnings Summary
INmune Bio Inc expected to post a loss of 50 cents a share - Earnings Preview
Brief: Inkmune Demonstrates Safety & Increased Nk-Cell Activity In First Dosing Cohort
Brief: INmune Bio Announces $13 Mln Registered Direct Offering
U.S. RESEARCH ROUNDUP-Aadi Bioscience, Target, Visteon
Brief: INmune Bio Says Entered Into Amended Sales Agreement Relating To Offer